Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.     

Details of the presentation are as follows:

Jefferies Gene Editing/Therapy SummitDate: Tuesday, October 11, 2016 Location: New York, New YorkTimes: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
[email protected]

Investor Contacts:

John Graziano
Trout Group
+1 646-378-2942
[email protected]

Chad Rubin
Trout Group
+1 646-378-2947
[email protected]

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform
• Sequential growth across all revenue streams
• Realkredit Danmark reports net profit of DKK 2,388 million for the first half of 2026